5:30 p.m.-8:00 p.m. Opening Remarks and Opening Keynote Session
Grand Ballroom
Session Chairperson: Cory Abate-Shen, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY

Modeling pancreatic cancer biology and medicine
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Developing therapeutics using the zebrafish
Leonard I. Zon, Children’s Hospital Boston, Boston, MA

8:00 p.m.-9:30 p.m. Opening Reception
Palm Terrace
Wednesday, November 6

7:00 a.m.-8:00 a.m.  Continental Breakfast
Palm Terrace

8:00 a.m.-10:00 a.m.  Plenary Session 1: Translational Successes from Model Organisms to the Clinic
Grand Ballroom
Session Chairperson: Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Boston, MA

8:00 a.m.  The Co-Clinical Trial Project
Pier Paolo Pandolfi

8:30 a.m.  Modeling APL pathogenesis through therapy response
Hugues de Thé, INSERM/CNRS, Paris, France

9:00 a.m.  Using cross-species analysis of genome-wide regulatory networks to identify drivers of cancer malignancy
Cory Abate-Shen, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY

9:30 a.m.  Paradoxical acceleration of pancreatic tumorigenesis through Smoothened inhibition: A post-clinical trial in genetically engineered mice*
Kenneth P. Olive, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY

9:45 a.m.  Targeting NOTCH1 and C-MYC in humanized models of relapsed and induction failure pediatric T-ALL*
Michelle A. Kelliher, University of Massachusetts Medical School, Worcester, MA

10:00 a.m.-10:30 a.m.  Break
Grand Ballroom Foyer East

*Short talks from proffered papers
10:30 a.m.-12:30 p.m. **Plenary Session 2: Target Discovery and Validation**
Grand Ballroom
*Session Chairperson: A. Thomas Look, Dana-Farber Cancer Institute, Boston, MA*

10:30 a.m. **Mining the proteome of mouse models of cancer for diagnostics and therapeutics**
Samir Hanash, The University of Texas MD Anderson Cancer Center, Houston, TX

11:00 a.m. **Drosophila cancer models identify complex therapeutics**
Ross L. Cagan, Mount Sinai School of Medicine, New York, NY

11:30 a.m. **BAP1: An emerging player in epigenetics and cancer***
Anwesha Dey, Genentech Inc., South San Francisco, CA

11:45 a.m. **A new class of drugs active in T-ALL is revealed in a zebrafish screen**
A. Thomas Look

12:15 p.m. **Linking development and cancer modeling in zebrafish identifies putative therapeutic targets in medullary thyroid cancer***
Jacques A. Villefranc, Weill Cornell Medical College, New York, NY

12:30 p.m.-2:30 p.m. **Poster Session A with Lunch**
The Gallery

*Short talks from proffered papers*
2:30 p.m.-4:30 p.m.  Plenary Session 3: Mechanisms of Resistance
Grand Ballroom
Session Chairperson: Cory Abate-Shen, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY

2:30 p.m.  Studying therapy response and resistance in mouse models of human breast cancer
Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands

3:00 p.m.  Targeting the immune environment in humanized mice model of breast cancer*
Te-Chia Wu, Baylor Institute for Immunology Research, Dallas, TX

3:15 p.m.  Improving existing cancer therapy by targeting the tumor microenvironment
Michael T. Hemann, David H. Koch Institute for Integrated Cancer Research at MIT, Cambridge, MA

3:45 p.m.  Clonal evolution enhances leukemia propagating cell activity in T-cell acutelymphoblastic leukemia through AKT/mTORC1 pathway activation*
Jessica Blackburn, Massachusetts General Hospital, Boston, MA

4:00 p.m.  Understanding drug responses and resistance mechanisms using imaging in live mice
Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

4:45 p.m.-6:45 p.m.  Panel Discussion: Barriers and Next Steps: Effective Preclinical Science for Cancer Patient Management
Grand Ballroom
Session Chairperson: Terry A. Van Dyke, National Cancer Institute-Frederick, Frederick, MD

Confirmed Panelists:
Anton J. M. Berns, Netherlands Cancer Institute, Amsterdam, The Netherlands
David Heimbrook, National Cancer Institute-Frederick/SAIC, Inc., Frederick, MD
Leisa Johnson, Genentech, Inc., South San Francisco, CA
Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Boston, MA
Nancy K. Pryer, Novartis Institutes for BioMedical Research, Emeryville, CA
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Terry A. Van Dyke

*Short talks from proffered papers
Thursday, November 7

7:00 a.m.-8:00 a.m.  Continental Breakfast
  Palm Terrace

8:00 a.m.-10:00 a.m.  Plenary Session 4: Integrating Studies from Model Organisms Using Genomic Approaches and Systems Biology
  Grand Ballroom
  Session Chairperson: Andrea Califano, Columbia University, New York, NY

  8:00 a.m.  The use of forward genetics for drug target discovery and the identification of mediators of therapy resistance
  David Adams, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

  8:30 a.m.  Interrogation of regulatory networks elucidates the genetic events leading to the mesenchymal subtype of glioblastoma
  Andrea Califano

  9:00 a.m.  Functional genomics and cancer vulnerabilities
  William Hahn, Dana-Farber Cancer Institute, Boston, MA

  9:30 a.m.  The Ras genetic network in cancer progression in mouse models
  Allan Balmain, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

10:00 a.m.-10:30 a.m.  Break
  Grand Ballroom Foyer East
10:30 a.m.-12:30 p.m.  Plenary Session 5: Emerging Technologies and Advances in Modeling
Grand Ballroom
Session Chairperson: Scott W. Lowe, Memorial Sloan-Kettering Cancer Center, New York, NY

10:30 a.m.  Accelerating translational research using ESC-GEMM models and inducible RNAi
Scott W. Lowe

11:00 a.m.  RNAi mouse models: Revolutionizing drug discovery in vivo*
Prem Premsrirut, Mirimus, Inc., Cold Spring Harbor, NY

11:15 a.m.  Identifying novel agents for treatment of childhood cancer: The PPTP experience
Peter Houghton, Nationwide Children’s Hospital, Columbus, OH

11:45 a.m.  Modeling human cancer therapeutic response: Evaluating the MAP kinase pathway in GEMMs, allografts, and patient-derived xenografts
Nancy K. Pryer, Novartis Institutes for BioMedical Research, Emeryville, CA

12:15 p.m.  Man’s best friend for cancer driver-passenger discrimination*
Shaying Zhao, University of Georgia, Athens, GA

12:30 p.m.-2:30 p.m.  Free Time/Lunch on Own

*Short talks from proffered papers
2:30 p.m.-4:30 p.m.  Plenary Session 6: Translational Mechanisms of Initiation and Progression
Grand Ballroom
Session Chairperson: Timothy C. Wang, Columbia University Medical Center, New York, NY

2:30 p.m.  Pathogenesis of gastric cancer: Lessons and therapeutic targets from mouse models
Timothy C. Wang

3:00 p.m.  Genetic interaction of NEDD9 with melanoma-prone oncogenes and tumor suppressor genes*
Minjung Kim, Moffitt Cancer Center, Tampa, FL

3:15 p.m.  From melanocyte to melanoma: Identifying key molecular events at the onset of cancer*
Charles K. Kaufman, Dana-Farber Cancer Institute, Boston, MA

3:30 p.m.  Canine cancer genetics: What dogs can tell us about ourselves
Elaine A. Ostrander, NIH-NHGRI, Bethesda, MD

4:00 p.m.  Advanced Avatar models for studying cancer stem cell dynamics in human pancreatic ductal adenocarcinoma*
Christopher Heeschen, Spanish National Cancer Research Centre (CNIO), Madrid, Madrid, Spain

4:15 p.m.  Directing personalized breast cancer treatment with pathway signatures*
Eran R. Andrechek, Michigan State University, East Lansing, MI

4:30 p.m.-6:30 p.m.  Poster Session B and Reception
The Gallery

*Short talks from proffered papers
Friday, November 8

7:00 a.m.-8:00 a.m.  Continental Breakfast
Palm Terrace

8:00 a.m.-10:00 a.m.  Plenary Session 7: Mechanisms of Cancer Progression and Metastases: Opportunities for Translation
Grand Ballroom
Session Chairperson: Anton J. M. Berns, Netherlands Cancer Institute, Amsterdam, The Netherlands

8:00 a.m.  Tumor heterogeneity and cell-of-origin of mouse small cell and non-small cell lung cancer
Anton J. M. Berns

8:30 a.m.  Modeling recurrent metastatic melanoma in the mouse
Glenn T. Merlino, National Cancer Institute, Bethesda, MD

9:00 a.m.  Using mouse models to identify and target key chromatin regulators in cancer
Karen Cichowski, Brigham and Women’s Hospital, Boston, MA

9:30 a.m.  Using a hypoxia-induced CSC tumor initiation model to improve predictive potential for patients with metastatic breast cancer*
Emily Chen, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY

9:45 a.m.  Quantitative and multiparameter analysis of tumor cell intravasation*
Elena I. Deryugina, The Scripps Research Institute, La Jolla, CA

10:00 a.m.-10:30 a.m.  Break
Grand Ballroom Foyer East

*Short talks from proffered papers
10:30 a.m.-12:30 p.m.  Plenary Session 8: Advances in Preclinical Studies
Grand Ballroom
Session Chairperson: Terry A. Van Dyke, National Cancer Institute-Frederick, Frederick, MD

10:30 a.m.  Genetic and preclinical evaluation of genetically engineered mouse models of lung cancer
Leisa Johnson, Genentech, Inc., South San Francisco, CA

11:00 a.m.  Therapeutic evaluation in genetically engineered cancer models
Terry A. Van Dyke

11:30 a.m.  Title to be announced
Kwok-Kin Wong, Dana-Farber Cancer Institute, Boston, MA

12:00 p.m.  Insights into acquired resistance to targeted therapies from mouse models of lung cancer
Katerina A. Politi, Yale Cancer Center, New Haven, CT

12:30 p.m.  Departure
UPCOMING CONFERENCES

Sixth Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
Co-Chairpersons: John D. Carpten, Christopher I. Li, and Olufunmilayo I. Olopade
December 6-9, 2013
Atlanta, GA

RAS Oncogenes: From Biology to Therapy
Co-Chairpersons: Dafna Bar-Sagi, Channing J. Der, and Frank McCormick
February 24-27, 2014
Lake Buena Vista, FL

Hematological Malignancies
Co-Chairpersons: Kenneth C. Anderson, Scott Armstrong, Riccardo Dalla-Favera, and Margaret Shipp
September 20-23, 2014
Philadelphia, PA

Melanoma
Co-Chairpersons: Levi A. Garraway, Keith T. Flaherty, and Suzanne L. Topalian
September 20-23, 2014
Philadelphia, PA

Cellular Heterogeneity in the Tumor Microenvironment
Co-Chairpersons: Mary Helen Barcellos-Hoff, Michele De Palma, and M. Celeste Simon
February 26-March 1, 2014
San Diego, CA

13th Annual International Conference on Frontiers in Cancer Prevention Research
Program Committee
Chairperson: Phillip A. Dennis
September 28-October 1, 2014
New Orleans, LA

Pancreatic Cancer
Co-Chairpersons: Dafna Bar-Sagi, David A. Tuveson, Christine Iacobuzio-Donahue, and Alec Kimmelman
May 18-21, 2014
New Orleans, LA

EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
Scientific Committee Co-Chairpersons: Jean-Charles Soria, Lee J. Helman, and Jeffrey A. Engelman
November 18-21, 2014
Barcelona, Spain

Targeting the PI3K-mTOR Network in Cancer
Co-Chairpersons: Lewis C. Cantley, Jose Baselga, Joan S. Brugge, Brendan J. Manning, and Malte Peters
September 14-17, 2014
Philadelphia, PA

Please visit www.aacr.org/meetingcalendar for additional conferences and program updates.